NCT02527265已完成2 期
Open-label, Single-arm, Multiple-dose Safety, Titration, and Pharmacokinetic Trial of Afrezza® in Pediatric Patients Ages 4 to 17 Years With Type 1 Diabetes Mellitus
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 13
- 主要终点
- Insulin Maximum Observed Concentration (Cmax)
研究概览
简要总结
Primary Objective:
-To assess the safety and tolerability of Afrezza in children ages 4 to 17 years with type 1 diabetes mellitus (T1DM).
Secondary Objectives:
- To assess the ability to titrate the prandial and supplemental doses of Afrezza at each meal.
- To assess pharmacokinetics (PK) following a prandial dose of Afrezza in children ages 4 to 17 years with T1DM.
详细描述
The patients are expected to participate in the study for approximately 6 to 8 weeks from Screening to final follow-up visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 4 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written or oral assent from the pediatric subject and written informed consent from the parent(s) or legal guardian and a witness, as required by both state and federal laws and the local Institutional Review Board;
- •Children aged ≥4 and ≤17 years (enrolled sequentially into 3 age cohorts: 13 to 17, 8 to 12, and 4 to 7 years);
- •Clinical diagnosis of T1DM and using insulin for at least 1 year;
- •Currently receiving a regimen of basal/bolus insulin administered by MDI for at least 6 weeks prior to enrollment;
- •Subjects with pre-breakfast self monitored blood glucose values between 80 and 250 mg/dL for 5 of 7 documented daily readings obtained in the week prior to Visit 2 (readings to be taken using glucometer provided at Screening Visit 1) and reported via the e Diary;
- •Subjects on a regimen of insulin via continuous SC insulin infusion may be enrolled if they satisfy all other enrollment criteria and are willing to convert to MDI for the duration of the study, beginning 6 weeks prior to enrollment. They must continue to meet all enrollment criteria after converting to the MDI regimen;
- •Total daily insulin dose ≤1.5 units/kg/day with a minimum of 3 units of RAA at every meal.
- •Hemoglobin A1c (HbA1c) ≥7.0% to <10.0% at the time of screening;
- •Fasting serum C-peptide ≤0.3 ng/mL;
- •Forced expiratory volume in 1 second (FEV1) ≥70% of National Health and Nutrition Examination Survey (NHANES) III predicted for children ≥8 years of age or Wang predicted for children <8 years of age;
- •Forced vital capacity ≥70% of NHANES III predicted for children ≥8 years of age or Wang predicted for children <8 years of age;
- •Females of childbearing potential, must use "highly effective" methods of contraception throughout conduct of the trial
排除标准
- •Body mass index below 25th or above 95th percentile for age and gender according to Centers for Disease Control and Prevention growth charts;
- •History of physician diagnosis of asthma or any other clinically important pulmonary disease, or use of any medications to treat such conditions within the last year;
- •Allergy or known hypersensitivity for AFREZZA or to drugs with similar chemical structure;
- •Unstable diabetes control, defined as 2 or more episodes of severe hypoglycemia (i.e., an episode associated with a seizure, coma, or loss of consciousness) or any hospitalization or emergency room visit for poor diabetes control, ketoacidosis, hypoglycemia, or hyperglycemia within the preceding 3 months from screening;
- •Serum creatinine ≥ the upper limit of normal for age;
- •Respiratory tract infection within 30 days before screening or between screening and initiation of treatment period; subject may return 4 weeks after resolution of the infection for rescreening;
- •Evidence of any complication of diabetes (proliferative retinopathy, autonomic neuropathy, nephropathy, etc), or likelihood of requiring laser photocoagulation, vitrectomy, or other specific treatment for diabetic retinopathy in the coming year;
- •Smoking of tobacco or other substances or positive urine cotinine testing (>100 ng/mL);
- •Positive urine drug screen;
- •Positive urine pregnancy test for female subjects of childbearing potential;
- •Inability to perform study procedures including pulmonary function testing;
- •Exposure to any investigational product(s) in the past 3 months or 5 half-lives, whichever is more;
- •History of eating disorder;
- •Any disease or exposure to any medication which, in the judgment of the principal Investigator, may impact glucose metabolism;
- •Any concurrent medical or major psychiatric condition that makes the subject unsuitable for the clinical study or impairs the subject's ability to participate in the study.
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究组 & 干预措施
Afrezza (Technosphere Insulin)
Experimental
Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.
During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day.
干预措施: Afrezza (Biological)
结局指标
主要结局
Insulin Maximum Observed Concentration (Cmax)
时间窗: 250 minutes post-dose
Insulin Cmax after a dose of Afrezza
次要结局
- Insulin Time to Reach Cmax (Tmax)(250 minutes post-dose)
- Insulin Area Under Concentration Time Curve (AUC)(250 minutes post-dose)
- Assessment of Fumaryl Diketopiperazine (FDKP) Elimination Half-life (t1/2)(Using PK data collected over 250 minutes post-dose of Afrezza)
研究者
研究点 (13)
Loading locations...
相似试验
已完成
3 期
Aripiprazole Open-Label, Safety and Tolerability StudySchizophreniaBipolar DisorderNCT00102518Otsuka Pharmaceutical Development & Commercialization, Inc.325
已完成
1 期
Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)Hypophosphatasia (HPP)NCT00744042Alexion Pharmaceuticals, Inc.11
终止
4 期
Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in ChildrenAttention Deficit/Hyperactivity DisorderNCT04987762Purdue Pharma LP103
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected ChildrenHIV InfectionsNCT00364793Bristol-Myers Squibb56
已完成
2 期
Study of Aripiprazole to Treat Children and Adolescents With AutismAutism Spectrum DisorderAutistic DisorderAsperger SyndromeNCT00619190University of North Carolina, Chapel Hill30